Business
Kristin Comella, U.S. Stem Cell's CSO, Co-Authored Paper Recognized as One of the Most Influential Scientific Papers of 2016 in the Journal of Translational Medicine
Kristin Comella, U.S. Stem Cell's CSO, Co-Authored Paper Recognized as One of the Most Influential Scientific Papers of 2016 in the Journal of Translational Medicine.
About this update from U.s. Stem Cell, Inc.
[{"type":"text","content":"SUNRISE, FL / ACCESSWIRE / June 12, 2017 / U.S. Stem Cell, Inc. (OTCQB: USRM), a scientific paper about intramyocardial implantation co-authored by Kristin Comella, Chief Science Officer at U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has been recognized as one of the most influential articles of 2016 for the Journal of Translational Medicine, according to Altmetric.com. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin's list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Comella has pioneered stem cell therapies from various sources including cord blood, bone marrow, muscle, and adipose. She led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. The paper, entitled \"Effects of the Intramyocardial Implantation of Stromal Vascular Fraction in Patients with Chronic Ischemic Cardiomyopathy,\" was co-authored by K. Comella, J. Parcero, H. Bansal, J. Perez, J. Lopez, A. Agrawal and T. Ichim and published in the Journal of Translational Medicine on June 2, 2016. 685 Article Accesses were tracked with an Almetric.com Attention Score of 254. Below is a link and abstract of the paper: https://www.ncbi.nlm.nih.gov/pubmed/27255774Background - Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue. The SVF contains a mixture of cells including ADSCs and growth factors and has been depleted of the adipocyte (fat cell) population. We evaluated the safety and efficacy of administering SVF intra-myocardially into patients with chronic ischemic cardiomyopathy.Methods - A total of 28 patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. The fat was separated to isolate the SVF and the cells were delivered into the akinetic myocardial scar region using a transendocardial delivery system (MyoCath®) in patients who had experienced a previous myocardial infarct. The subjects were then monitored for adverse events, ejection fraction via echocardiogram and six-minute walk test...